Regeneron Q3 revenue rises 1% to $3.75 billion; non-GAAP EPS falls 5% to $11.83
Regeneron reported third quarter 2025 total revenues of $3.75 billion, up 1% from a year earlier, and GAAP diluted EPS of $13.62, up 18%. Non-GAAP diluted EPS fell 5% to $11.83, and EYLEA franchise U.S. net sales declined 28% to $1.11 billion, while the company narrowed or lowered several full-year 2025 expense guidance ranges and raised its GAAP effective tax rate guidance to approximately 14%.
Key points
- Total revenues $3.754 billion vs. $3.721 billion in Q3 2024; Dupixent global net sales recorded by Sanofi rose 27% to $4.86 billion.
- GAAP net income rose 9% to $1.460 billion, helped by $578 million in net gains on securities; non-GAAP net income fell 12% to $1.287 billion.
- Full-year 2025 guidance: GAAP R&D and non-GAAP SG&A ranges lowered; GAAP effective tax rate raised to approximately 14% from 11%–13%.
- Board declared a $0.88 per share dividend payable December 5, 2025; $2.156 billion remained available for share repurchases as of September 30, 2025.
The filing
Written by AI on Nov 8, 2026, 1:21 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 28, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.